Haloperidol Neuraxpharm (Haloperidol Decanoate)

Haloperidol Neuraxpharm is prescribed for several psychiatric indications where a long‑acting injectable antipsychotic is suitable, offering clinicians a depot option to improve adherence and maintain symptom control.

• Schizophrenia maintenance therapy in adults.
• Acute psychotic episodes requiring rapid stabilization.
• Chronic psychosis where oral adherence is problematic.
• Adjunctive treatment in patients with treatment‑resistant psychotic disorders.
• Off‑label use for severe agitation in controlled settings when clinically justified.
• Long‑term prophylaxis to reduce relapse risk in patients stabilized on oral haloperidol.
• Use in combination with oral antipsychotics during transition to depot therapy.

The safety profile of haloperidol decanoate includes a range of effects that vary in frequency and clinical significance.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Weight gain or changes in appetite.
• Blurred vision or other visual disturbances.
• Orthostatic hypotension.
• Elevated liver enzymes.
• Skin rash or pruritus.
• Elevated prolactin levels leading to sexual dysfunction.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Torsades de pointes or other serious cardiac arrhythmias.
• Hyperprolactinemia with galactorrhea or menstrual disturbances.
• Severe depression or suicidal thoughts.
• Significant leukopenia or neutropenia.

When prescribing haloperidol decanoate, clinicians should consider several precautionary measures to minimize risks and ensure appropriate patient monitoring.

• Assess for a history of cardiovascular disease, including arrhythmias or prolonged QT interval.
• Evaluate for prior extrapyramidal reactions or tardive dyskinesia before initiating therapy.
• Monitor serum prolactin levels in patients who develop galactorrhea, menstrual changes, or sexual dysfunction.
• Use caution in elderly patients and those with hepatic or renal impairment, adjusting dose as needed.
• Screen for neuroleptic malignant syndrome signs, especially during the first weeks of treatment.
• Discuss pregnancy and lactation considerations with women of childbearing potential, as safety data are limited.

Haloperidol decanoate may interact with other medications that affect its metabolism, cardiac conduction, or central nervous system effects, requiring careful review of a patient’s drug regimen.

Avoid

• Concomitant use with other potent dopamine antagonists, which can exacerbate extrapyramidal symptoms.
• Co‑administration with QT‑prolonging agents such as certain antiarrhythmics, fluoroquinolones, or macrolide antibiotics.
• Combining with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase haloperidol plasma concentrations.

Use with caution

• Use with other CNS depressants (e.g., benzodiazepines, opioids) as additive sedation may occur.
• Caution when prescribing with anticholinergic drugs, which can mask early signs of neuroleptic malignant syndrome.
• Adjust dose when used with CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce therapeutic effect.